XML 61 R29.htm IDEA: XBRL DOCUMENT
v3.20.4

Segments | 12 Months Ended
--- | ---
Dec. 31, 2020
Segment Reporting [Abstract] |
Segments | Segments The Company realigned its business in April 2019, and as a result, its CODM began regularly reviewing disaggregated financial information for various operating segments. The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) loss on impairment of goodwill and other noncurrent assets, (viii) equity in net loss of affiliates, and (ix) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. For the year ended December 31, 2020, the Company modified the current period definition of Segment Adjusted EBITDA to exclude adjustments recorded to reverse the difference of bonuses accrued as of December 31, 2019 compared to the value of equity awards granted, as the Company determined in March 2020 that those accrued bonuses would be paid through the grant of equity awards instead of cash. The Company also excluded noncash losses associated with settlement agreements. Segment Adjusted EBITDA for the years ended December 31, 2019 and 2018, were not impacted by these changes. Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the businesses included in the Transactions and the operations of MBP Titan which are reported as discontinued operations (Note 3). For the year ended December 31, 2020, the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) Trans Ova, and (iv) the Human Biotherapeutics division. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December 31, 2020. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. The Company's Human Biotherapeutics division is an operating division within Precigen which in 2020 and 2019 included the Company's majority-owned subsidiary, Triple-Gene LLC, and its collaborations with Castle Creek (Note 6). The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to be reported separately. Information by reportable segment was as follows:
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Goodwill |  |  |  |  |  |  |  |  |  |  |  |  |
Balances at December 31, 2018 | $ | 15,232 |  |  | $ | 1,788 |  |  |  |  | $ | 46,236 |  |  | $ | — |  |  | $ | 20,736 |  |  | $ | 83,992 |
Reallocations from changes to reporting units | — |  |  | — |  |  |  |  | — |  |  | 482 |  |  | (482) |  |  | — |
Impairments | — |  |  | — |  |  |  |  | (29,642) |  |  | — |  |  | (178) |  |  | (29,820) |
Foreign currency translation adjustments | — |  |  | (53) |  |  |  |  | — |  |  | — |  |  | — |  |  | (53) |
Balances at December 31, 2019 | 15,232 |  |  | 1,735 |  |  |  |  | 16,594 |  |  | 482 |  |  | 20,076 |  |  | 54,119 |
Foreign currency translation adjustments | — |  |  | 244 |  |  |  |  | — |  |  | — |  |  | — |  |  | 244 |
Balances at December 31, 2020 | $ | 15,232 |  |  | $ | 1,979 |  |  |  |  | $ | 16,594 |  |  | $ | 482 |  |  | $ | 20,076 |  |  | $ | 54,363 |
| Year Ended December 31, 2020
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Revenues from external customers | $ | 776 |  |  | $ | 3,053 |  |  |  |  | $ | 71,186 |  |  | $ | 17,810 |  |  | $ | 10,299 |  |  | $ | 103,124 |
Intersegment revenues | 5,006 |  |  | (3) |  |  |  |  | 340 |  |  | — |  |  | 281 |  |  | 5,624 |
Total segment revenues | $ | 5,782 |  |  | $ | 3,050 |  |  |  |  | $ | 71,526 |  |  | $ | 17,810 |  |  | $ | 10,580 |  |  | $ | 108,748 |
Segment Adjusted EBITDA | $ | (25,611) |  |  | $ | (7,861) |  |  |  |  | $ | 2,624 |  |  | $ | (2,139) |  |  | $ | 4,274 |  |  | $ | (28,713) |
| Year Ended December 31, 2019
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Revenues from external customers | $ | 2,227 |  |  | $ | (364) |  |  |  |  | $ | 68,672 |  |  | $ | 3,713 |  |  | $ | 12,514 |  |  | $ | 86,762 |
Intersegment revenues | 11,341 |  |  | 498 |  |  |  |  | 1,361 |  |  | — |  |  | 1,270 |  |  | 14,470 |
Total segment revenues | $ | 13,568 |  |  | $ | 134 |  |  |  |  | $ | 70,033 |  |  | $ | 3,713 |  |  | $ | 13,784 |  |  | $ | 101,232 |
Segment Adjusted EBITDA | $ | (30,164) |  |  | $ | (13,662) |  |  |  |  | $ | (6,337) |  |  | $ | (1,051) |  |  | $ | (4,901) |  |  | $ | (56,115) |
| Year Ended December 31, 2018
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Revenues from external customers | $ | 29,021 |  |  | $ | 6,684 |  |  |  |  | $ | 75,178 |  |  | $ | — |  |  | $ | 30,213 |  |  | $ | 141,096 |
Intersegment revenues | 617 |  |  | 840 |  |  |  |  | 558 |  |  | — |  |  | 255 |  |  | 2,270 |
Total segment revenues | $ | 29,638 |  |  | $ | 7,524 |  |  |  |  | $ | 75,736 |  |  | $ | — |  |  | $ | 30,468 |  |  | $ | 143,366 |
Segment Adjusted EBITDA | $ | (32,832) |  |  | $ | (12,797) |  |  |  |  | $ | (5,730) |  |  | $ | — |  |  | $ | (10,708) |  |  | $ | (62,067) |
The table below reconciles total segment revenues from reportable segments to total consolidated revenues:
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018
Total segment revenues from reportable segments | $ | 98,168 |  |  | $ | 87,448 |  |  | $ | 112,898 |
Other revenues, including from other operating segments | 10,634 |  |  | 17,964 |  |  | 40,841 |
Elimination of intersegment revenues | (5,624) |  |  | (14,690) |  |  | (2,561) |
Total consolidated revenues | $ | 103,178 |  |  | $ | 90,722 |  |  | $ | 151,178 |
The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018
Segment Adjusted EBITDA for reportable segments | $ | (32,987) |  |  | $ | (51,214) |  |  | $ | (51,359) |
All Other Segment Adjusted EBITDA | 4,274 |  |  | (4,901) |  |  | (10,708) |
Remove cash paid for capital expenditures and investments in affiliates | 6,970 |  |  | 12,512 |  |  | 15,276 |
Add recognition of previously deferred revenue associated with upfront and milestone payments | 25,005 |  |  | 14,721 |  |  | 33,204 |
Other expenses: |  |  |  |  |
Interest expense | (18,400) |  |  | (17,666) |  |  | (8,473) |
Depreciation and amortization | (15,042) |  |  | (16,142) |  |  | (20,612) |
Impairment losses | (920) |  |  | (30,810) |  |  | — |
Reacquisition of in-process research and development | — |  |  | — |  |  | (236,748) |
Loss on settlement agreement | (11,436) |  |  | — |  |  | — |
Stock-based compensation expense | (19,746) |  |  | (15,098) |  |  | (30,554) |
Adjustment related to accrued bonuses paid in equity awards | 2,833 |  |  | — |  |  | — |
Equity in net loss of affiliates | (1,138) |  |  | (2,416) |  |  | (8,986) |
Other | 11 |  |  | 67 |  |  | — |
Unallocated corporate costs | (37,566) |  |  | (46,011) |  |  | (74,609) |
Eliminations | (5,713) |  |  | (14,306) |  |  | (2,343) |
Consolidated net loss from continuing operations before income taxes | $ | (103,855) |  |  | $ | (171,264) |  |  | $ | (395,912) |
As of December 31, 2020 and 2019, the Company had $5,908 and $6,724, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $595, $1,401, and $6,255 for the years ended December 31, 2020, 2019 and 2018, respectively.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration